Vittal Vasista's most recent trade in Regenxbio Inc was a trade of 20,041 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 19, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Vasista Vittal | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2024 | 20,041 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 19 Mar 2024 | 20,041 | 246,534 (0%) | 0% | 3.8 | 75,354 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 76,313 | 76,313 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Vasista Vittal | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 16,026 | 226,493 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Vasista Vittal | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.95 per share. | 02 Jan 2024 | 4,534 | 210,467 (0%) | 0% | 17.9 | 81,385 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2023 | 35,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 31 May 2023 | 35,000 | 215,001 (0%) | 0% | 0.9 | 29,750 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 66,233 | 66,233 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 46,174 | 180,001 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.68 per share. | 03 Jan 2023 | 1,333 | 133,827 (0%) | 0% | 22.7 | 30,232 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.24 per share. | 30 Aug 2022 | 2,400 | 135,160 (0%) | 0% | 30.2 | 72,573 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.19 per share. | 04 Aug 2022 | 17,280 | 137,560 (0%) | 0% | 35.2 | 608,035 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 04 Aug 2022 | 400 | 154,840 (0%) | 0% | 35 | 14,000 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.26 per share. | 01 Aug 2022 | 2,400 | 155,240 (0%) | 0% | 31.3 | 75,012 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.01 per share. | 13 Jul 2022 | 4,332 | 158,108 (0%) | 0% | 30.0 | 129,988 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 13 Jul 2022 | 468 | 157,640 (0%) | 0% | 30 | 14,040 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 20 Jan 2022 | 29,900 | 162,440 (0%) | 0% | 0.9 | 25,415 | Common Stock |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2022 | 29,900 | 35,000 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 42,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 8,900 | 132,540 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2021 | 10,000 | 64,900 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Vittal Vasista | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 27 Jul 2021 | 10,000 | 123,640 (0%) | 0% | 0.9 | 8,500 | Common Stock |